RxDoctor Payments Data

Rhonda Wilson

Psychiatric/Mental Health · Swainsboro, GANPI 1780162610

Payments from drug & device makers

$2,717in general payments, 2019–2025

Across 131 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$406
  • AbbVie$368
  • Axsome Therapeutics, Inc.$300
  • Alkermes, Inc.$269
  • Vanda Pharmaceuticals Inc.$234
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$214
  • plus $925 from 11 others

What the payments were for

  • Food & beverage$2,717100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,717 in reported general payments places this provider in the 85th percentile of 900 psychiatric/mental health providers in Georgia.

See all psychiatric/mental health providers in Georgia

Medicare billing

Part B allowed, 2024
$20,290
Medicare patients
50
Services billed
270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide11$5,411
Aripiprazole22$593
Venlafaxine Hcl ErVenlafaxine Hcl29$412
Trazodone Hcl61$344
Buspirone Hcl26$335
Divalproex Sodium21$332
Bupropion XlBupropion Hcl15$290
Escitalopram Oxalate12$288
Bupropion Hcl SrBupropion Hcl21$225
Olanzapine19$223
Quetiapine Fumarate22$194
Duloxetine Hcl11$181
Risperidone21$180
Hydroxyzine Pamoate17$169
Lamotrigine31$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$68$5,41111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatric/mental health providers in Georgia.

Other psychiatric/mental health in Swainsboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →